 Stephen Humphries
Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, X-Ray Computed | 53 | 2026 | 2770 | 5.270 |
Why?
| | Lung Diseases, Interstitial | 21 | 2026 | 664 | 4.470 |
Why?
| | Pulmonary Emphysema | 20 | 2026 | 277 | 3.620 |
Why?
| | Idiopathic Pulmonary Fibrosis | 24 | 2026 | 692 | 3.490 |
Why?
| | Pulmonary Fibrosis | 10 | 2026 | 395 | 2.910 |
Why?
| | Lung | 40 | 2026 | 4116 | 2.090 |
Why?
| | Emphysema | 8 | 2024 | 100 | 1.950 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 18 | 2026 | 920 | 1.740 |
Why?
| | Sinusitis | 6 | 2024 | 227 | 1.160 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 5 | 2026 | 122 | 1.120 |
Why?
| | Paranasal Sinuses | 4 | 2024 | 81 | 0.990 |
Why?
| | Arthritis, Rheumatoid | 5 | 2025 | 1180 | 0.880 |
Why?
| | Disease Progression | 20 | 2026 | 2865 | 0.840 |
Why?
| | Vital Capacity | 10 | 2025 | 292 | 0.840 |
Why?
| | Image Interpretation, Computer-Assisted | 3 | 2020 | 288 | 0.760 |
Why?
| | Mucin-5B | 6 | 2026 | 234 | 0.730 |
Why?
| | Rhinitis | 5 | 2024 | 169 | 0.670 |
Why?
| | Aged | 36 | 2026 | 26212 | 0.610 |
Why?
| | Middle Aged | 40 | 2026 | 36297 | 0.570 |
Why?
| | Olfaction Disorders | 4 | 2024 | 70 | 0.570 |
Why?
| | Cystic Fibrosis | 6 | 2025 | 1163 | 0.570 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 7 | 2025 | 373 | 0.560 |
Why?
| | Humans | 81 | 2026 | 145750 | 0.540 |
Why?
| | Smokers | 3 | 2024 | 138 | 0.510 |
Why?
| | Male | 50 | 2026 | 72992 | 0.480 |
Why?
| | Respiratory Function Tests | 6 | 2025 | 544 | 0.460 |
Why?
| | Indoles | 3 | 2026 | 507 | 0.450 |
Why?
| | Female | 50 | 2026 | 79025 | 0.450 |
Why?
| | Algorithms | 6 | 2026 | 1850 | 0.450 |
Why?
| | Severity of Illness Index | 9 | 2025 | 2933 | 0.420 |
Why?
| | Bronchi | 1 | 2015 | 263 | 0.410 |
Why?
| | Alveolitis, Extrinsic Allergic | 2 | 2026 | 93 | 0.400 |
Why?
| | Scleroderma, Systemic | 2 | 2025 | 123 | 0.390 |
Why?
| | Prognosis | 8 | 2026 | 4329 | 0.390 |
Why?
| | Forced Expiratory Volume | 9 | 2025 | 450 | 0.370 |
Why?
| | Prospective Studies | 16 | 2025 | 8075 | 0.350 |
Why?
| | Models, Statistical | 1 | 2015 | 672 | 0.340 |
Why?
| | Retrospective Studies | 14 | 2026 | 17322 | 0.330 |
Why?
| | Cohort Studies | 8 | 2025 | 6032 | 0.320 |
Why?
| | Autoimmune Diseases | 2 | 2025 | 469 | 0.320 |
Why?
| | Bleomycin | 3 | 2026 | 255 | 0.300 |
Why?
| | Smoking | 4 | 2024 | 1477 | 0.290 |
Why?
| | Smell | 3 | 2024 | 126 | 0.280 |
Why?
| | Aminophenols | 3 | 2025 | 203 | 0.260 |
Why?
| | Lung Diseases | 2 | 2026 | 782 | 0.260 |
Why?
| | Pulmonary Artery | 2 | 2024 | 1129 | 0.240 |
Why?
| | Matrix Metalloproteinase 12 | 1 | 2026 | 7 | 0.240 |
Why?
| | Australia | 2 | 2026 | 291 | 0.220 |
Why?
| | Densitometry | 1 | 2025 | 36 | 0.220 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2026 | 241 | 0.220 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2026 | 98 | 0.210 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2026 | 280 | 0.200 |
Why?
| | Artificial Intelligence | 2 | 2026 | 381 | 0.200 |
Why?
| | Spirometry | 4 | 2026 | 233 | 0.200 |
Why?
| | Benzodioxoles | 1 | 2025 | 161 | 0.200 |
Why?
| | Radiation Dosage | 1 | 2025 | 193 | 0.200 |
Why?
| | Sputum | 1 | 2025 | 302 | 0.190 |
Why?
| | Reproducibility of Results | 5 | 2026 | 3416 | 0.190 |
Why?
| | Predictive Value of Tests | 3 | 2024 | 2123 | 0.190 |
Why?
| | Quinolones | 1 | 2025 | 204 | 0.190 |
Why?
| | Radiography, Thoracic | 2 | 2023 | 172 | 0.190 |
Why?
| | Respiratory Mucosa | 1 | 2025 | 322 | 0.190 |
Why?
| | Lung Injury | 1 | 2026 | 249 | 0.190 |
Why?
| | ROC Curve | 3 | 2026 | 618 | 0.180 |
Why?
| | Transforming Growth Factor beta | 1 | 2025 | 474 | 0.180 |
Why?
| | Bronchiectasis | 1 | 2024 | 115 | 0.180 |
Why?
| | Sulfonamides | 1 | 2026 | 583 | 0.180 |
Why?
| | Adult | 18 | 2026 | 40867 | 0.170 |
Why?
| | Pseudomonas Infections | 1 | 2023 | 230 | 0.170 |
Why?
| | Genetic Predisposition to Disease | 4 | 2026 | 2399 | 0.170 |
Why?
| | Pyridines | 1 | 2025 | 609 | 0.170 |
Why?
| | Pulmonary Surfactant-Associated Protein C | 1 | 2021 | 45 | 0.170 |
Why?
| | Protein C | 1 | 2021 | 54 | 0.160 |
Why?
| | Fibroblasts | 1 | 2026 | 1027 | 0.160 |
Why?
| | Chronic Disease | 5 | 2026 | 1810 | 0.160 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2021 | 115 | 0.160 |
Why?
| | Radiology | 1 | 2022 | 174 | 0.160 |
Why?
| | Quality of Life | 5 | 2025 | 3210 | 0.160 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 229 | 0.150 |
Why?
| | Principal Component Analysis | 2 | 2020 | 194 | 0.150 |
Why?
| | Transcriptome | 1 | 2025 | 1043 | 0.140 |
Why?
| | Models, Cardiovascular | 1 | 2020 | 196 | 0.140 |
Why?
| | Minimal Clinically Important Difference | 1 | 2018 | 31 | 0.140 |
Why?
| | Heart Ventricles | 2 | 2021 | 756 | 0.140 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2021 | 248 | 0.140 |
Why?
| | Neuroendocrine Cells | 1 | 2018 | 33 | 0.140 |
Why?
| | Apoptosis | 1 | 2026 | 2443 | 0.130 |
Why?
| | Fontan Procedure | 1 | 2020 | 192 | 0.130 |
Why?
| | Aged, 80 and over | 3 | 2019 | 8346 | 0.130 |
Why?
| | Echocardiography, Doppler | 1 | 2018 | 115 | 0.130 |
Why?
| | Body Mass Index | 1 | 2026 | 2447 | 0.130 |
Why?
| | Data Interpretation, Statistical | 1 | 2018 | 368 | 0.120 |
Why?
| | Diagnosis, Differential | 3 | 2026 | 1512 | 0.120 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2018 | 214 | 0.120 |
Why?
| | Arthritis, Experimental | 1 | 2018 | 136 | 0.120 |
Why?
| | Longitudinal Studies | 4 | 2025 | 2967 | 0.120 |
Why?
| | Biomarkers | 5 | 2026 | 4302 | 0.110 |
Why?
| | Collagen | 1 | 2018 | 457 | 0.110 |
Why?
| | Demography | 1 | 2015 | 282 | 0.110 |
Why?
| | Epithelial Cells | 1 | 2021 | 1134 | 0.110 |
Why?
| | Hemodynamics | 1 | 2020 | 1118 | 0.110 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2018 | 394 | 0.110 |
Why?
| | Genetic Variation | 1 | 2019 | 976 | 0.100 |
Why?
| | Military Personnel | 1 | 2022 | 737 | 0.100 |
Why?
| | Chloride Channel Agonists | 2 | 2025 | 110 | 0.100 |
Why?
| | Follow-Up Studies | 4 | 2025 | 5428 | 0.100 |
Why?
| | Mutation | 5 | 2022 | 4090 | 0.100 |
Why?
| | Pulmonary Diffusing Capacity | 2 | 2026 | 78 | 0.100 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2019 | 992 | 0.100 |
Why?
| | Risk Factors | 6 | 2025 | 10916 | 0.100 |
Why?
| | Obesity | 1 | 2026 | 3118 | 0.090 |
Why?
| | Treatment Outcome | 5 | 2025 | 11793 | 0.090 |
Why?
| | Dyspnea | 2 | 2025 | 250 | 0.090 |
Why?
| | Case-Control Studies | 2 | 2018 | 3634 | 0.090 |
Why?
| | Computer Simulation | 1 | 2015 | 1003 | 0.080 |
Why?
| | Logistic Models | 1 | 2015 | 2139 | 0.080 |
Why?
| | Asthma | 1 | 2022 | 1797 | 0.080 |
Why?
| | Proportional Hazards Models | 2 | 2024 | 1330 | 0.080 |
Why?
| | X-Ray Microtomography | 2 | 2021 | 108 | 0.070 |
Why?
| | Clinical Trials as Topic | 2 | 2025 | 1062 | 0.070 |
Why?
| | Genotype | 2 | 2025 | 1857 | 0.070 |
Why?
| | Forecasting | 2 | 2020 | 390 | 0.060 |
Why?
| | Postoperative Complications | 1 | 2020 | 2977 | 0.060 |
Why?
| | Phenotype | 2 | 2026 | 3170 | 0.060 |
Why?
| | Registries | 2 | 2026 | 2410 | 0.060 |
Why?
| | Child | 4 | 2024 | 22738 | 0.060 |
Why?
| | Infant | 3 | 2018 | 10089 | 0.060 |
Why?
| | Mice | 4 | 2026 | 18357 | 0.060 |
Why?
| | Bronchitis, Chronic | 1 | 2025 | 16 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 6084 | 0.060 |
Why?
| | Airway Remodeling | 1 | 2025 | 63 | 0.060 |
Why?
| | United States | 4 | 2025 | 16122 | 0.050 |
Why?
| | Pyrrolidines | 1 | 2025 | 125 | 0.050 |
Why?
| | Twins, Conjoined | 1 | 2004 | 6 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2025 | 272 | 0.050 |
Why?
| | Young Adult | 2 | 2025 | 14250 | 0.050 |
Why?
| | Machine Learning | 2 | 2020 | 587 | 0.050 |
Why?
| | Uncertainty | 1 | 2025 | 146 | 0.050 |
Why?
| | Quinolines | 1 | 2025 | 190 | 0.050 |
Why?
| | Drug Combinations | 1 | 2025 | 396 | 0.050 |
Why?
| | Quantitative Trait Loci | 1 | 2026 | 381 | 0.050 |
Why?
| | Prevalence | 2 | 2022 | 2874 | 0.050 |
Why?
| | Pulmonary Veins | 1 | 2024 | 108 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2025 | 5921 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2025 | 421 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2026 | 5992 | 0.050 |
Why?
| | Molecular Epidemiology | 1 | 2022 | 74 | 0.040 |
Why?
| | Preoperative Care | 1 | 2004 | 380 | 0.040 |
Why?
| | Pyrazoles | 1 | 2025 | 517 | 0.040 |
Why?
| | Diagnostic Imaging | 1 | 2004 | 337 | 0.040 |
Why?
| | Lung Volume Measurements | 1 | 2021 | 46 | 0.040 |
Why?
| | Pyridones | 1 | 2023 | 209 | 0.040 |
Why?
| | Time Factors | 2 | 2024 | 7133 | 0.040 |
Why?
| | Protective Factors | 1 | 2021 | 99 | 0.040 |
Why?
| | Genetic Markers | 1 | 2022 | 338 | 0.040 |
Why?
| | Walk Test | 1 | 2021 | 81 | 0.040 |
Why?
| | Societies, Medical | 1 | 2025 | 900 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2022 | 251 | 0.040 |
Why?
| | Animals | 4 | 2026 | 38100 | 0.040 |
Why?
| | Survival Rate | 1 | 2025 | 2094 | 0.040 |
Why?
| | Total Lung Capacity | 1 | 2020 | 29 | 0.040 |
Why?
| | Fibrosis | 1 | 2023 | 561 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2025 | 838 | 0.040 |
Why?
| | Child, Preschool | 1 | 2015 | 11866 | 0.040 |
Why?
| | Surface-Active Agents | 1 | 2021 | 98 | 0.040 |
Why?
| | Adolescent | 2 | 2020 | 22569 | 0.040 |
Why?
| | Air | 1 | 2020 | 44 | 0.040 |
Why?
| | Patient-Specific Modeling | 1 | 2020 | 45 | 0.040 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2019 | 75 | 0.040 |
Why?
| | Coronary Circulation | 1 | 2020 | 134 | 0.040 |
Why?
| | Idiopathic Interstitial Pneumonias | 1 | 2019 | 44 | 0.040 |
Why?
| | Genome-Wide Association Study | 1 | 2026 | 1430 | 0.040 |
Why?
| | Ventricular Function, Right | 1 | 2021 | 297 | 0.040 |
Why?
| | Cigarette Smoking | 1 | 2020 | 102 | 0.030 |
Why?
| | Myocardial Contraction | 1 | 2020 | 293 | 0.030 |
Why?
| | Treatment Failure | 1 | 2019 | 360 | 0.030 |
Why?
| | Heart Failure, Diastolic | 1 | 2018 | 23 | 0.030 |
Why?
| | Health Status | 1 | 2023 | 835 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2023 | 2064 | 0.030 |
Why?
| | Hyperplasia | 1 | 2018 | 177 | 0.030 |
Why?
| | Rare Diseases | 1 | 2018 | 116 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2022 | 498 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2021 | 583 | 0.030 |
Why?
| | Telomerase | 1 | 2019 | 246 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2018 | 428 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2022 | 789 | 0.030 |
Why?
| | Linear Models | 1 | 2018 | 849 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2020 | 578 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2026 | 4569 | 0.030 |
Why?
| | Autoantibodies | 1 | 2023 | 1509 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2018 | 1300 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2019 | 1247 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1378 | 0.030 |
Why?
| | Stroke Volume | 1 | 2018 | 655 | 0.030 |
Why?
| | Software | 1 | 2020 | 680 | 0.030 |
Why?
| | Pandemics | 1 | 2023 | 1711 | 0.030 |
Why?
| | Databases, Factual | 1 | 2020 | 1491 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 2000 | 0.020 |
Why?
| | Comorbidity | 1 | 2018 | 1662 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1751 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2023 | 1925 | 0.020 |
Why?
| | Smoking Cessation | 1 | 2016 | 441 | 0.020 |
Why?
| | Colorado | 1 | 2019 | 4556 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 3752 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2020 | 3915 | 0.020 |
Why?
| | Models, Anatomic | 1 | 2004 | 87 | 0.010 |
Why?
| | Brain | 1 | 2004 | 2969 | 0.010 |
Why?
|
|
Humphries's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|